Status:
COMPLETED
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis
Lead Sponsor:
Dr. med. Micha Loebermann
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-70 years
Brief Summary
The aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(MS) under MS-specific therapy.
Detailed Description
Protective vaccines against communicable diseases are of major importance in patients with autoimmune diseases or impaired immune response. In patients with multiple sclerosis bacterial or viral infec...
Eligibility Criteria
Inclusion
- Established diagnosis of Multiple Sclerosis
- Age: 18 - 70 years
- Indication for vaccination (according to public recommendation)
- Written informed consent
Exclusion
- Current relapse of MS
- Unstable disease
- Contraindication for vaccination (acute infection, fever, allergy to vaccine)
- Unable to comply with study procedures
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT02275741
Start Date
October 1 2009
End Date
November 1 2016
Last Update
November 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rostock
Rostock, Germany, 18057